CAPP2 highlighted as an Advance in Progress Against Cancer

posted on Thursday, 18th February 2021

Not tagged.

[#pageName]

The CAPP2 clinical trial led by Professor Sir John Burn, Newcastle University, has been highlighted by the American Society of Clinical Oncology as an Advance in Progress Against Cancer in their 16th Annual Report. The CAPP2 long term follow up paper was published in the Lancet in 2020.

It is a significant step for this cancer chemoprevention research to be noted by the American Society of Clinical Oncology.

CaPP3 is the follow up dose non-inferiority trial  to determine if this cancer chemoprevention can be observed with a lower dose of aspirin.

 

Share this!

Latest News

  • 17

    Apr

    2024

    Last Newcastle Recruit

    posted on Wednesday, 17th April 2024
    Last Newcastle Recruit

    "Delighted to see Robin, our last Newcastle recruit to CaPP3 for his five year follow up" - Professor Sir John Burn

    Not tagged.

    Comments (0)

  • 04

    Apr

    2024

    Lynch Choices website: now inviting patients to complete digital feedback surveys

    posted on Thursday, 4th April 2024

    Lynch Choices have started sharing the beta version of the Lynch Choices patient decision support website, containing information including personalised cancer risks via a link to the Prospective Lynch Syndrome Database, patients stories and signposting to resources and charities, to complement shared-decision making with healthcare professionals. 

    Not tagged.

    Comments (0)

bentley gt dark sapphire watch officine panerai firenze 1860 divers professional op 6541 uk replica watches iwc replica watches reviews valjoux 7730 replica watches uk tag formula 1 calibre 16 price baselworld 2018 rolex predictions fake watches oyster perpetual datejust breitling a24322 movement replica watch vendome hublot geneve collection 582888 price iced out rolex watches for sale fake watches